Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","amount":"$39.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD\/MAD Clinical Trials of GM-1020","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Gilgamesh Pharmaceuticals

    Menu

    Gilgamesh Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Gilgamesh Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder

              Details:

              The funding aims to support the company's ongoing development of GM-3009 (ibogaine), a Kappa opioid receptor agonist. It is evaluated in the Preclinical trials for the treatment of Opioid-Related Disorders.

              Lead Product(s): Ibogaine

              Therapeutic Area: Psychiatry/Psychology Product Name: GM-3009

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute on Drug Abuse

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding March 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Gilgamesh Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020

              Details:

              GM-1020 is a novel, oral NMDA receptor antagonist with the potential of advancing a new treatment option for patients with major depressive disorders and other neuropsychiatric conditions.

              Lead Product(s): GM-1020

              Therapeutic Area: Psychiatry/Psychology Product Name: GM-1020

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Gilgamesh Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

              Details:

              GM-1020 is a novel, patented (composition of matter), orally active small molecule antagonist of the N-methyl-D-aspartate (NMDA) receptor with the potential to have rapid-acting antidepressant (RAAD) activity without adverse behavioral effects at therapeutic doses.

              Lead Product(s): GM-1020

              Therapeutic Area: Psychiatry/Psychology Product Name: GM-1020

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Prime Movers Lab

              Deal Size: $39.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing December 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY